Conflict of interest declaration: Brian G Feagan

Roles in: IBD Group

1. In the past three years have you accepted the following from an organisation that may gain or lose financially from the publication of reviews by your review group in the Cochrane Database of Systematic Reviews (CDSR)?

a) Reimbursement for attending a conference or symposium (including travel, accommodation and/or hospitality)?
No

b) Fees for speaking?
Yes - Abbott/AbbVie, JnJ/Janssen, Lilly, Takeda, Tillotts, UCB Pharma

c) Fees for organising education?
No

d) Funds for research?
Yes - AbbVie Inc., Amgen Inc., AstraZeneca/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline (GSK), Janssen Research & Development LLC., Pfizer Inc., Receptos Inc. / Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG, UCB

e) Funds for a member of staff?
No

f) Fees for consulting?
Yes - Abbott/AbbVie, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, Astra Zeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer-Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestles, Nextbiotix, Novonordisk, ParImmune, Parvus Therapeutics Inc., Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Qu Biologics, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., Zyngenia

g) Royalty payments?
No

2. In the past three years have you or your spouse/partner been employed by an organization that may in any way gain or lose financially from the publication of reviews by your review group in the CDSR?
No

3. Do you own stocks or shares in companies that may gain or lose financially from the publication of reviews by your review group in the CDSR?
No

4. Do you hold any patents for products that that may lead you to gain or lose financially from the publication of reviews by your review group in the CDSR?
No

5. Do you have any other competing interests (financial or non-financial)?
Yes - Member, Scientific Advisory Board: Abbott/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Galapagos, Genentech/Roche, JnJ/Janssen, Merck, Nestles, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, UCB Pharma